Coloplast reported a mixed bag for Q3 16 with sales slightly below while net profit marginally ahead of our as well as consensus expectations. Revenue was up by 4% to DKK3.7bn with organic growth of 8%, limited by a negative currency impact of 4% on account of currency depreciation (particularly that of the GBP, ARS and USD against the DKK). At the segment level, Ostomy Care and Urology Care lead the pack, recording organic growth of +11% and +8%, respectively. However, contrary to the previo
05 Sep 2016
Decent quarter, driven by Ostomy and Urology, but challenges ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decent quarter, driven by Ostomy and Urology, but challenges ahead
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
05 Sep 2016 -
Author:
Jyoti Prakash -
Pages:
4
Coloplast reported a mixed bag for Q3 16 with sales slightly below while net profit marginally ahead of our as well as consensus expectations. Revenue was up by 4% to DKK3.7bn with organic growth of 8%, limited by a negative currency impact of 4% on account of currency depreciation (particularly that of the GBP, ARS and USD against the DKK). At the segment level, Ostomy Care and Urology Care lead the pack, recording organic growth of +11% and +8%, respectively. However, contrary to the previo